Application of 5 '-tiRNA-Lys-CTT as liver cancer serum early diagnosis marker

By using 5'-tiRNA-Lys-CTT as a detection target in liver cancer diagnosis and combining abnormal prothrombin or alpha-fetoprotein combined with the combined diagnosis of abnormal prothrombin or alpha-fetoprotein, the problem of insufficient sensitivity of early diagnosis of liver cancer in the prior art has been solved, and a higher level of The detection sensitivity and specificity of the patient has improved the diagnostic efficacy and 5-year survival rate of patients with stage 0/A of liver cancer.

CN118995935AInactive Publication Date: 2024-11-22AFFILIATED HOSPITAL OF NANTONG UNIV

Patent Information

Application Number
CN202411340769.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-25
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The lack of technical solutions for the application and treatment of tsRNAs in liver cancer in the diagnosis and treatment of liver cancer in the prior art, resulting in insufficient sensitivity and accuracy of early diagnosis of liver cancer, especially in the limitations of imaging and existing markers such as AFP and APT. Down.

Method used

Using 5'-tiRNA-Lys-CTT as the detection target, the method of total RNA extraction, reverse transcription and fluorescence quantitative PCR detection was used to identify and quantify the content of 5'-tiRNA-Lys-CTT in serum samples to improve the The sensitivity and specificity of early diagnosis of liver cancer, combined with abnormal prothrombin or alpha-fetoprotein for joint diagnosis.

Benefits of technology

Verification experiments show that 5'-tiRNA-Lys-CTT is significantly upregulated in serum and tumor tissues of early liver cancer patients, with high detection sensitivity and specificity, better than traditional markers AFP and APT, and improves BCLC 0/ The diagnostic efficacy of stage A patients provides a new biomarker, which is simple and easy to implement, and is suitable as an early screening indicator, improving the 5-year survival rate of liver cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995935A_ABST
    Figure CN118995935A_ABST
Patent Text Reader

Abstract

The invention provides application of 5 '-tiRNA-Lys-CTT as a liver cancer serum early diagnosis marker, and relates to the technical field of research and development of biological diagnosis reagents, the specific technical scheme is that the application of 5'-tiRNA-Lys-CTT as a detection target in preparation of liver cancer early diagnosis products, and specific verification experiments prove that the serum 5 '-tiRNA-Lys-CTT can be used for early diagnosis of liver cancer. Particularly, the 5 '-tiRNA-Lys-CTT is obviously up-regulated in serum and tumor tissues of a patient in the 0 / A stage of BCLC, which indicates that the 5'-tiRNA-Lys-CTT is closely related to the liver cancer. ROC analysis shows that the serum 5 '-tiRNA-Lys-CTT has a good distinguishing effect on a BCLC 0 / A stage liver cancer patient and a healthy person, the distinguishing effect is better than that of alpha fetoprotein and abnormal prothrombin (vitamin K deficiency or antagonist-II induced protein), and a new biomarker is provided for early diagnosis of the liver cancer patient. Serum samples are easy to obtain, and blood examination of suspected patients can be used as an early screening index, so that early treatment is facilitated, and the five-year survival rate of liver cancer is increased; and compared with imageology and invasive examination, the device is simpler and more convenient and can be accepted by patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biological diagnostic reagent research, and in particular to the application of 5'-tiRNA-Lys-CTT as an early diagnosis marker for liver cancer serum. Background Art

[0002] Primary liver cancer mainly includes three different pathological types: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and HCC-ICC mixed type. Among them, HCC is the most common pathological type of liver cancer, accounting for 85%-90%. At present, HCC has become the third leading cause of cancer death in the world due to its high recurrence rate and poor prognosis. Primary liver cancer has an insidious onset. Most of them are in the local advanced stage or have distant metastasis when diagnosed. The 5-year survival rate of the advanced stage is about 15%, while the 5-year survival rate of early liver cancer is about 75%. Therefore, early diagnosis is the key to improving prognosis. At present, the diagnosis of HCC mainly relies on imaging diagnosis and monitoring of serum markers such as alpha-fetoprotein (AFP), abnormal prothrombin (PIVKA-II, APT), and viral copy number. However, the sensitivity of imaging diagnosis of early liver cancer is only 47%, and the sensitivity of AFP diagnosis is 52.9%. In addition, about 30% of liver cancer patients show AFP negative. Therefore, it is necessary to find new early diagnostic markers for liver cancer to improve the early screening effect of clinical liver cancer. In addition, there is still no good treatment for patients with advanced or metastatic or drug-resistant HCC. It is also very important to deeply explore the regulatory mechanism that induces the malignant progression of HCC and find effective therapeutic targets.

[0003] Non-coding RNA (ncRNA) is a genomic transcription product that does not have the function of encoding proteins. Studies in recent years have shown that dysregulated expression of ncRNA is closely related to the occurrence and development of tumors. Because of its tissue specificity and the fact that it can be easily and stably detected in human tissues and body fluids, more and more studies have begun to focus on the application potential of ncRNA as a tumor diagnostic marker. Transfer RNA (tRNA) is a classic type of ncRNA, and in 1979, tRNA-derived small RNA (tsRNA) was first discovered in cancer patients, indicating that tsRNAs are involved in expression and play a regulatory role in cancer.

[0004] tsRNAs are a type of non-coding small RNA produced by specific endoribonucleases cleaving at different positions on precursor tRNA or mature tRNA. According to the different cleavage sites, they can be divided into two categories: tRNA-derived fragments (tRFs) and tRNA halves (tiRNAs). tsRNAs can play biological roles through a variety of regulatory mechanisms, including interacting with proteins or mRNAs to regulate gene expression, epigenetic modification, and cell cycle. Some studies have found that the dysregulation of tsRNAs is closely related to the occurrence and development of tumors through high-throughput sequencing technology. However, there are currently few studies on the occurrence and development of tsRNAs in liver cancer. Finding dysregulated tsRNAs in liver cancer and exploring their specific mechanisms of action are of great significance for the early diagnosis and treatment of liver cancer. Summary of the invention

[0005] The purpose of the present invention is to solve the technical problem that the prior art lacks the application of tsRNAs that are unregulated in liver cancer in the diagnosis and treatment of liver cancer.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] The application of 5'-tiRNA-Lys-CTT as a detection target in the preparation of an early diagnosis product for liver cancer. The base sequence number of the 5'-tiRNA-Lys-CTT is shown in SEQ NO: 01.

[0008] Preferably, the diagnostic product is a detection reagent or a detection kit

[0009] Preferably, the test sample of the diagnostic product is a serum sample, and the diagnostic product is used to diagnose patients with BCLC stage 0 / A liver cancer.

[0010] Preferably, the liver cancer early diagnosis product also uses abnormal prothrombin or alpha-fetoprotein as detection targets for combined diagnosis.

[0011] A product for early diagnosis of liver cancer, characterized in that: the diagnostic product uses serum 5'-tiRNA-Lys-CTT as a detection target.

[0012] A method for detecting the content of 5'-tiRNA-Lys-CTT in a sample for non-diagnostic purposes, characterized by comprising three steps of total RNA extraction, reverse transcription, and fluorescence quantitative PCR detection.

[0013] Preferably, the reverse transcription PCR primer sequence is 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGTCTCA-3'.

[0014] Preferably, the forward primer sequence of the fluorescent quantitative PCR detection is: 5'-GGCTAGCTCAGTCGGTAGAGCA-3';

[0015] The reverse primer sequence was: 5'-AGTGCAGGGTCCGAGGTATT-3'.

[0016] In this application, through specific verification experiments, it is proved that serum 5'-tiRNA-Lys-CTT is significantly upregulated in the early stage of liver cancer, especially in the serum and tumor tissues of patients with BCLC 0 / A stage, suggesting that 5'-tiRNA-Lys-CTT is closely related to liver cancer. ROC analysis shows that serum 5'-tiRNA-Lys-CTT has a good discriminatory effect between BCLC 0 / A stage liver cancer patients and healthy people, and the discriminatory effect is better than alpha-fetoprotein and abnormal prothrombin. This provides a new biomarker for the early diagnosis of liver cancer patients and has excellent clinical application value. Serum samples are easy to obtain, and blood tests for suspected patients can be used as early screening indicators to facilitate early treatment and improve the 5-year survival rate of liver cancer; compared with imaging and invasive examinations, it is simpler and more acceptable to patients. Compared with the existing liver cancer markers AFP and APT, 5'-tiRNA-Lys-CTT has higher detection sensitivity and specificity. If combined with the joint diagnosis of other markers, it can improve the detection sensitivity on the one hand and the accuracy of diagnosis on the other hand. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a method for obtaining 5'-tiRNA-Lys-CTT by cleavage in one embodiment of the present invention, which is cleaved by tRNA-Lys-CTT-2-1, and the cleavage position and sequence are marked in the figure;

[0018] Figure 2 The amplification curve of 5'-tiRNA-Lys-CTT amplified by fluorescent quantitative PCR in one embodiment of the present invention (A); the amplified product was subjected to gel electrophoresis to show good specificity (B); the amplified product was subjected to Sanger sequencing, and the sequence was consistent (C);

[0019] Figure 3In one embodiment of the present invention, the RNA was left for 6 hours, 12 hours, 18 hours and 24 hours, and the CT values ​​of 5'-tiRNA-Lys-CTT were detected without statistical difference (A); the RNA was repeatedly frozen and thawed 1 time, 3 times, 5 times and 10 times, and the CT values ​​of 5'-tiRNA-Lys-CTT were detected without statistical difference (B).

[0020] Figure 4 5'-tiRNA-Lys-CTT expression level in 50 pairs of liver cancer patient cancer tissues and adjacent tissues in one embodiment of the present invention, wherein (A); the expression level of 5'-tiRNA-Lys-CTT in the serum of 110 liver cancer patients was significantly higher than that of healthy controls (B); the 110 patients were classified according to stage, tumor size, alpha-fetoprotein (AFP) concentration, and whether they were infected with hepatitis B, and the expression level of 5'-tiRNA-Lys-CTT was statistically analyzed, and the results showed that the expression level of 5'-tiRNA-Lys-CTT was associated with these clinical pathological information (C); the expression level of 5'-tiRNA-Lys-CTT in serum was positively correlated with the corresponding AFP concentration, and the expression level of 5'-tiRNA-Lys-CTT in tissues and corresponding serum was positively correlated (D).

[0021] Figure 5 This is a comparison chart of the detection effects of 5'-tiRNA-Lys-CTT, alpha-fetoprotein (AFP) and abnormal prothrombin (APT) in early liver cancer (BCLC stage 0 / A) in one embodiment of the present invention. DETAILED DESCRIPTION

[0022] The present invention is further described in detail below in conjunction with specific embodiments.

[0023] The application of 5'-tiRNA-Lys-CTT as a detection target in the preparation of an early diagnosis product for liver cancer, wherein the base sequence number of the 5'-tiRNA-Lys-CTT is shown in SEQ NO: 01; the diagnostic product is a detection reagent or a detection kit.

[0024] The detection sample of the diagnostic product is a serum sample, and the diagnostic product is used to diagnose patients with BCLC stage 0 / A liver cancer.

[0025] Preferably, the liver cancer early diagnosis product also uses abnormal prothrombin or alpha-fetoprotein as detection targets for combined diagnosis.

[0026] The present application also provides a product for early diagnosis of liver cancer, wherein the diagnostic product uses serum 5'-tiRNA-Lys-CTT as a detection target.

[0027] The present application also provides a method for detecting the content of 5'-tiRNA-Lys-CTT in a sample for non-diagnostic purposes, which comprises the following steps: total RNA extraction, reverse transcription, and fluorescence quantitative PCR detection.

[0028] Wherein, the reverse transcription PCR primer sequence is

[0029] 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGTCTCA-3',

[0030] The forward primer sequence for the fluorescent quantitative PCR detection is:

[0031] 5'-GGCTAGCTCAGTCGGTAGAGCA-3'

[0032] The reverse primer sequence was: 5'-AGTGCAGGGTCCGAGGTATT-3'.

[0033] The above contents are explained below in combination with specific verification experiments.

[0034] S1: Experimental materials:

[0035] Clinical blood samples were collected from 110 sera of liver cancer patients who had not received cancer-related treatment in the sample library of Nantong University Affiliated Hospital, 50 pairs of cancer tissue and adjacent tissue of liver cancer patients, and 110 sera of healthy controls. The relevant case information was obtained through the clinical electronic medical record system of Nantong University Affiliated Hospital. The research in this application was approved by the Ethics Committee of Nantong University Affiliated Hospital, with the ethics number: 2023-L059.

[0036] S2: Experimental methods:

[0037] 1. Extraction of Total RNA from Serum

[0038] According to the instructions of the total RNA purification and isolation kit, extract the total RNA of the serum sample according to the steps. Take out the patient serum sample from the -80℃ refrigerator and dissolve it on ice. Pipette 250μL of serum sample into a 1.5mL enzyme-free EP tube, add 750μL of lysis solution, vortex vigorously for 1min, let stand at room temperature for 5min, and fully lyse the sample. Add 200μL of chloroform, vortex for 15s, and let stand at room temperature for 3min. Centrifuge for 10min at 4℃, 12000r / min. The sample is stratified by the naked eye, and carefully pipette about 600μL of the upper liquid into a new enzyme-free EP tube. Add the same volume of freshly prepared 70% ethanol (600μL) and mix thoroughly by inversion. Transfer the mixed liquid to the adsorption column RA, and centrifuge for 1min at 4℃, 10000r / min. Pour out the liquid in the collection tube and put the adsorption column back into the collection tube. Add 500μL of rinse solution RW, 500μL of deproteinized solution RE, 500μL of rinse solution RW, 500μL of rinse solution RW in sequence, centrifuge at 4℃, 12000r / min for 1min. After adding deproteinized solution RE, let stand at room temperature for 2min. Pour out the liquid in the collection tube each time, put the adsorption column back into the collection tube, centrifuge at 4℃, 12000r / min for 2min, and fully remove the residual liquid. Take out the adsorption column, place it on the enzyme-free EP tube, add 30μL of preheated DEPC water in the center of the adsorption column, and let stand at room temperature for 2min. Centrifuge at 4℃, 12000r / min for 1min, add the liquid in the EP tube to the adsorption column again, and repeat the operation once. Measure and mark the concentration and purity of total RNA, place on ice for use or store in a -80℃ refrigerator.

[0039] 2. Total RNA Extraction from Cell and Tissue Samples

[0040] Total RNA of cell and tissue samples was extracted using Trizol reagent according to the steps. For cell samples, cells were collected by trypsin digestion, and cells were resuspended and washed with PBS. The cell suspension was transferred to a 1.5 mL enzyme-free EP tube, centrifuged at 1000 r / min for 3 min, and washed twice. After PBS was completely aspirated, 1 mL Trizol Reagen was added, and the samples were repeatedly blown and vortexed for 10 min. For tissue samples, they were thawed on ice, 60 mg of tissue was placed in a 1.5 mL enzyme-free EP tube and cut into pieces, 0.5 mL Trizol Reagen was added, and the tissue was fully ground and lysed on ice using a tissue variable speed grinder, and 0.5 mL Trizol Reagen was added again and vortexed for 10 min. 200 μL of chloroform was added to the above EP tube, and milky white flocs appeared. The precipitate was dissolved by vortexing vigorously for 15 s, and then placed on ice for 3 min. Centrifuged at 4 ° C, 12000 r / min for 15 min. After centrifugation, the sample can be seen to be layered. If the layering is not obvious, the centrifugation time can be appropriately increased. Carefully pipette about 600μL of the upper liquid into a new enzyme-free EP tube. Add the same volume of isopropanol (600μL), invert and mix to avoid violent shaking, and place on ice for 15min. Centrifuge at 4℃, 12000r / min for 15min. Small pieces of white gelatinous precipitate can be seen at the bottom of the EP tube with the naked eye, and the supernatant is gently discarded. Add 1mL of freshly prepared, pre-cooled 75% ethanol to the precipitate, and gently invert and wash the precipitate. Centrifuge at 4℃, 7500r / min for 5min, discard the supernatant, and carefully remove the residual ethanol on the tube wall with a 10μL pipette tip. Open the EP tube and place it in a 50℃ constant temperature drying oven for incubation for 5-10min until the precipitate becomes transparent. Add 20-30μL preheated DEPC water and blow and mix, and place it in a 60℃ constant temperature drying oven for incubation for 10min to fully dissolve the RNA precipitate. Measure the concentration and purity of the total RNA sample and mark it on the tube wall. Place it on ice until use or store it in a -80°C freezer.

[0041] 3. Reverse Transcription Reaction

[0042] According to the RNA concentration, 1000 ng was taken for reaction quantification, and the reverse transcription PCR reaction was performed in a total volume of 10 μL or 20 μL. The reverse transcription PCR conditions were set as follows: 25°C for 5 min, 42°C for 60 min, 70°C for 5 min, and maintained at 4°C. The reverse transcription primer sequence was 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGTCTCA-3', and the reverse transcription reaction system was shown in Table 1.

[0043] Table 1 Reverse transcription reaction system

[0044]

[0045]

[0046] 4. Real-time quantitative PCR (qRT-PCR)

[0047] The qRT-PCR reaction was performed in a total volume of 20 μL. The qRT-PCR reaction conditions were set as follows: 95°C pre-denaturation for 10 min, 95°C denaturation for 10 s, 60°C annealing and extension for 34 s, for a total of 40 cycles. The forward primer sequence was 5'-GGCTAGCTCAGTCGGTAGAGCA-3', and the reverse primer sequence was 5'-AGTGCAGGGTCCGAGGTATT-3'. The reaction system of qRT-PCR is shown in Table 2. Using U6 as the internal reference, the relative expression of 5'-tiRNA-Lys-CTT was calculated using the 2-△△Ct algorithm, △△Ct = experimental group (Ct target gene-CtU6)-control group (Ct target gene-CtU6). Alternatively, a standard curve was drawn using a standard product, and the corresponding concentration was calculated using the CT value of 5'-tiRNA-Lys-CTT.

[0048] Table 2 qRT-PCR reaction system

[0049]

[0050] 5. Agarose gel electrophoresis and Sanger sequencing

[0051] Use distilled water (ddH 2 O) Dilute 50×TAE to 1×TAE. The usual amount used for each electrophoresis is 980 mL ddHO 2O+20mL 50×TAE. Measure 120mL 1×TAE solution and pour it into a beaker, and keep the remaining 1×TAE aside. Add 2.4g agarose powder to the beaker, place it in a microwave oven and heat it repeatedly on high heat for 1min, stir with a glass rod to accelerate dissolution and remove bubbles. When the agarose solution is completely dissolved and becomes clear and transparent, stop heating and let it stand at room temperature to cool to 50-60℃. Add 6μL 10000×GeneRed Nucleic Acid Dye, shake and stir to mix, and then quickly pour it into the gel preparation tank. The solution thickness is about 0.5cm. Insert the comb vertically to avoid bubbles. If bubbles are generated, use the gun tip to prick them. Place it horizontally at room temperature. When the gel becomes milky white, indicating that it is completely cooled and solidified, pull out the comb vertically, place it in the electrophoresis tank, and pour 1×TAE solution to cover the gel. Add 6μL DNAMarker as an indicator and a mixture of 5μL PCR amplification product and 1μL 6×Loading Buffer to the loading well. After loading, adjust the gel to be perpendicular to the current direction, set the voltage to 110V, and the electrophoresis time to 30-60min. The electrophoresis time can be adjusted according to the position of the band. After the electrophoresis is completed, take out the gel and place it under a multifunctional imager for observation and imaging. After the observation is completed, cut the gel at the position of the band and the PCR product stock solution and send it to Guangzhou Jisai Biological Company for Sanger sequencing.

[0052] 6. Statistical Analysis

[0053] The experimental data were analyzed and plotted using SPSS20.0 and GraphpadPrism 10.0 software. A scatter plot was drawn using a bilateral unpaired t-test and a paired t-test to describe the relative expression of 5'-tiRNA-Lys-CTT in liver cancer patients' cancer and adjacent tissues. A scatter plot was drawn using a bilateral unpaired t-test to describe the relative expression of 5'-tiRNA-Lys-CTT in the serum of liver cancer patients, and a single-factor analysis of variance was used to compare multiple independent samples. The ROC curve and the area under the curve (Area under the curve, AUC) were used to evaluate the diagnostic performance of 5'-tiRNA-Lys-CTT for early liver cancer. Before drawing the ROC curve, binomial logistic regression statistics were performed in this application to calculate the Youden index = specificity + sensitivity -1 to evaluate the authenticity of the screening experiment. Multivariate analysis was performed using the Cox proportional hazard regression model, and the hazard ratio and its 95% confidence interval for each parameter were recorded. All experiments were repeated at least three times independently, and the data were listed as mean ± standard deviation. P < 0.05 was considered statistically significant, and P values ​​were annotated with *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 in the text.

[0054] S3: Conclusion

[0055] 1. Structural information of 5'-tiRNA-Lys-CTT

[0056] See also Figure 1 , 5'-tiRNA-Lys-CTT is cleaved from tRNA-Lys-CTT-2-1 and is a 32nt 5'-tiRNA with the base sequence:

[0057] 5'-GCCCGGCTAGCTCAGTCGGTAGAGCATGAGAC-3'.

[0058] 2. Molecular accuracy of amplification product identification

[0059] See also Figure 2 In order to verify the amplification accuracy of the qRT-PCR product, the amplification product was detected by agarose gel electrophoresis in this application, showing a bright single band of about 80 bp, which was consistent with the predicted size of the target gene product. After cloning and amplification, Sanger sequencing confirmed that the product was the full-length sequence of 5'-tiRNA-Lys-CTT.

[0060] 3. Stability of serum 5'-tiRNA-Lys-CTT

[0061] See also Figure 3 , 20 different serum samples were mixed, and the mixed serum samples were placed at room temperature for 0, 6, 12, 18, and 24 hours, or repeatedly frozen and thawed for 0, 1, 3, 5, and 10 times, and the CT value of 5'-tiRNA-Lys-CTT was detected. The results showed that there was no statistical difference in the CT value changes of 5'-tiRNA-Lys-CTT in the above experiments (P>0.05), indicating that its expression in serum is highly stable and is not easily affected by changes in external conditions.

[0062] 4. Expression of 5'-tiRNA-Lys-CTT in tissues and serum of patients with liver cancer

[0063] See also Figure 4, qRT-PCR was used to detect the expression of 5'-tiRNA-Lys-CTT in 50 pairs of liver cancer tissues and adjacent tissues. The expression of 5'-tiRNA-Lys-CTT in cancer tissues was significantly higher than that in adjacent tissues. qRT-PCR was used to detect the expression of 5'-tiRNA-Lys-CTT in the serum of 110 liver cancer patients and 110 healthy subjects. The expression of 5'-tiRNA-Lys-CTT in the serum of liver cancer patients was significantly higher than that in healthy subjects. The pathological information of the 110 patients was classified and statistically analyzed. The expression of 5'-tiRNA-Lys-CTT was significantly increased in the early stage of liver cancer (BCLC 0 / A stage); patients with larger tumor volume had higher expression of 5'-tiRNA-Lys-CTT; patients with a history of hepatitis B had higher expression of 5'-tiRNA-Lys-CTT. Moreover, the expression level of 5'-tiRNA-Lys-CTT was positively correlated with the AFP concentration of the same patient, as well as the expression of 5'-tiRNA-Lys-CTT in the tissues of the same patient, indicating that the expression of 5'-tiRNA-Lys-CTT was related to the clinical information of the patient and was related to the progression of the patient's disease.

[0064] 5. Diagnostic efficacy of 5'-tiRNA-Lys-CTT in serum of patients with BCLC stage 0 / A liver cancer

[0065] See also Figure 5 The ROC curve was drawn based on the expression level of 5'-tiRNA-Lys-CTT in the serum of BCLC 0 / A liver cancer patients and healthy controls. The ROC curve showed that the area under the curve of 5'-tiRNA-Lys-CTT was 0.770, which was higher than 0.694 of APT and 0.680 of AFP, and had a good diagnostic efficacy that was superior to traditional tumor markers. The combined diagnostic efficacy of 5'-tiRNA-Lys-CTT, APT and AFP was 0.883. The combined diagnosis of the three can greatly improve the detection sensitivity and accuracy.

[0066] In summary, the present application study shows that serum 5'-tiRNA-Lys-CTT is significantly upregulated in the early stage of liver cancer, especially in the serum and tumor tissue of patients with BCLC 0 / A stage, suggesting that 5'-tiRNA-Lys-CTT is closely related to liver cancer. ROC analysis shows that serum 5'-tiRNA-Lys-CTT has a good discriminatory effect between BCLC 0 / A stage liver cancer patients and healthy people, and the discriminatory effect is better than alpha-fetoprotein (AFP) and abnormal prothrombin (APT). This provides a new biomarker for the early diagnosis of liver cancer patients and has excellent clinical application value. Serum samples are easy to obtain, and blood tests for suspected patients can be used as early screening indicators to facilitate early treatment and improve the 5-year survival rate of liver cancer; compared with imaging and invasive examinations, it is simpler and more acceptable to patients. Compared with the existing liver cancer markers AFP and APT, 5'-tiRNA-Lys-CTT has higher detection sensitivity and specificity. If combined with the joint diagnosis of other markers, it can improve the detection sensitivity on the one hand and the accuracy of diagnosis on the other hand.

Claims

1. Application of 5'-tiRNA-Lys-CTT as a detection target in the preparation of early diagnosis products for liver cancer. Features: The base sequence number of the 5'-tiRNA-Lys-CTT is shown in SEQ NO:

01.

2. The use of 5'-tiRNA-Lys-CTT according to claim 1 as a detection target in the preparation of an early diagnosis product for liver cancer, characterized in that: The diagnostic product is a detection reagent or a detection kit.

3. The use of 5'-tiRNA-Lys-CTT according to claim 1 as a detection target in the preparation of an early diagnosis product for liver cancer, characterized in that: The test sample of the diagnostic product is a serum sample, and the diagnostic product is used to diagnose patients with BCLC0 / A stage liver cancer.

4. The use of 5'-tiRNA-Lys-CTT according to claim 1 as a detection target in the preparation of an early diagnosis product for liver cancer, characterized in that: The liver cancer early diagnosis product also uses APT or AFP as a detection target for combined diagnosis.

5. A product for early diagnosis of liver cancer, characterized by: The diagnostic product uses serum 5'-tiRNA-Lys-CTT as a detection target.

6. A method for detecting the content of 5'-tiRNA-Lys-CTT in a sample for non-diagnostic purposes, characterized in that: It includes three steps: total RNA extraction, reverse transcription, and fluorescence quantitative PCR detection.

7. The method for detecting the content of 5'-tiRNA-Lys-CTT in a sample for non-diagnostic purposes according to claim 6, characterized in that: The reverse transcription PCR primer sequence is 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGTCTC A-3'.

8. The method for detecting the content of 5'-tiRNA-Lys-CTT in a sample for non-diagnostic purposes according to claim 6, characterized in that: The forward primer sequence of the fluorescent quantitative PCR detection is: 5'-GGCTAGCTCAGTCGGTAGAGCA-3'; The reverse primer sequence was: 5'-AGTGCAGGGTCCGAGGTATT-3'.

Citation Information

Patent Citations

  • TsRNA marker for diagnosing systemic lupus erythematosus and clinical application

    CN113355407A

  • Novel tumor marker for hepatocellular carcinoma and clinical application thereof

    US20230242996A1

Cited By

  • TsRNA biomarker for hepatocellular carcinoma diagnosis and prognosis and application of tsRNA biomarker

    CN121137151A

  • A tsRNA biomarker for the diagnosis and prognosis of hepatocellular carcinoma and its application

    CN121137151B